• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

关于偏头痛的治疗。二氢麦角胺口服控释制剂在人体中的药代动力学-药效学关系。

On the treatment of migraine. Pharmacokinetic-pharmacodynamic relationships for a programmed release formulation of dihydroergotamine administered orally in the human.

作者信息

Aylward M, Davies D E, Maddock J, Robinson P R, Jones M

出版信息

Cephalalgia. 1983 Aug;3 Suppl 1:146-50. doi: 10.1177/03331024830030S123.

DOI:10.1177/03331024830030S123
PMID:6616596
Abstract

With the combined pharmacokinetic-pharmacodynamic approach, the bioavailability and venoconstrictor effects of two DHE formulations (programmed release capsules and oral solution) have been compared after acute oral dose administrations in the healthy volunteer subjects. The bioavailability of DHE from programmed release capsules has been significantly greater than that shown by the oral solution. DHE capsules formulation has seemed to provide appropriate plasma concentrations for at least 10 h after administration. That may well account for its efficacy in the treatment of morning migraine.

摘要

采用药代动力学-药效学联合方法,在健康志愿者受试者中急性口服给药后,比较了两种去氢表雄酮制剂(缓释胶囊和口服溶液)的生物利用度和血管收缩作用。缓释胶囊中去氢表雄酮的生物利用度显著高于口服溶液。去氢表雄酮胶囊制剂给药后似乎能在至少10小时内维持适当的血浆浓度。这很可能解释了其在治疗晨起偏头痛方面的疗效。

相似文献

1
On the treatment of migraine. Pharmacokinetic-pharmacodynamic relationships for a programmed release formulation of dihydroergotamine administered orally in the human.关于偏头痛的治疗。二氢麦角胺口服控释制剂在人体中的药代动力学-药效学关系。
Cephalalgia. 1983 Aug;3 Suppl 1:146-50. doi: 10.1177/03331024830030S123.
2
[Treatment of morning migraine. Clinical and biokinetic correlation of programmed-release dihydroergotamine].[早晨偏头痛的治疗。缓释二氢麦角胺的临床与生物动力学相关性]
Presse Med. 1984 Jun 23;13(26):1617-9.
3
Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy.载甲磺酸二氢麦角胺的聚维酮溶解型微针贴片用于急性偏头痛治疗管理。
J Control Release. 2017 Dec 28;268:159-165. doi: 10.1016/j.jconrel.2017.10.021. Epub 2017 Oct 16.
4
Human pharmacokinetics of dihydroergotamine administered by nasal spray.经鼻喷雾给药的双氢麦角胺的人体药代动力学。
Clin Pharmacol Ther. 1996 Sep;60(3):265-75. doi: 10.1016/S0009-9236(96)90053-3.
5
Orally inhaled dihydroergotamine: a review.口服二氢麦角胺:综述。
Headache. 2013 Sep;53 Suppl 2:43-53. doi: 10.1111/head.12184.
6
Bioavailability of dihydroergotamine in man.双氢麦角胺在人体中的生物利用度。
Br J Clin Pharmacol. 1982 Jun;13(6):785-90. doi: 10.1111/j.1365-2125.1982.tb01866.x.
7
Is orally inhaled dihydroergotamine (DHE) equivalent in efficacy in migraine to intravenous DHE?
Headache. 2014 Feb;54(2):383. doi: 10.1111/head.12269.
8
Dihydroergotamine: pharmacokinetics, pharmacodynamics, and mechanism of venoconstrictor action in beagle dogs.
J Cardiovasc Pharmacol. 1987 Jun;9(6):686-93.
9
MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.MAP0004,经口吸入 DHE:急性偏头痛治疗的一项随机对照研究。
Headache. 2011 Apr;51(4):507-17. doi: 10.1111/j.1526-4610.2011.01869.x.
10
Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration.
Eur J Clin Pharmacol. 1986;30(5):581-4. doi: 10.1007/BF00542418.

引用本文的文献

1
The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care.PROMISE研究:法国初级保健中使用SEglor(甲磺酸双氢麦角胺)预防偏头痛
CNS Drugs. 2004;18(15):1149-63. doi: 10.2165/00023210-200418150-00009.